跳轉至內容
Merck
  • Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function.

Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function.

Immunity (1998-08-11)
O Adachi, T Kawai, K Takeda, M Matsumoto, H Tsutsui, M Sakagami, K Nakanishi, S Akira
摘要

MyD88, originally isolated as a myeloid differentiation primary response gene, is shown to act as an adaptor in interleukin-1 (IL-1) signaling by interacting with both the IL-1 receptor complex and IL-1 receptor-associated kinase (IRAK). Mice generated by gene targeting to lack MyD88 have defects in T cell proliferation as well as induction of acute phase proteins and cytokines in response to IL-1. Increases in interferon-gamma production and natural killer cell activity in response to IL-18 are abrogated. In vivo Th1 response is also impaired. Furthermore, IL-18-induced activation of NF-kappaB and c-Jun N-terminal kinase (JNK) is blocked in MyD88-/- Th1-developing cells. Taken together, these results demonstrate that MyD88 is a critical component in the signaling cascade that is mediated by IL-1 receptor as well as IL-18 receptor.